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Background: Access to timely and accurate diagnostic tests has a significant impact in the management of
diseases of global concern such as malaria. While molecular diagnostics satisfy this need effectively in developed
countries, barriers in technology, reagent storage, cost and expertise have hampered the introduction of these
methods in developing countries. In this study a simple, lab-on-chip PCR diagnostic was created for malaria that
overcomes these challenges.
Methods: The platform consists of a disposable plastic chip and a low-cost, portable, real-time PCR machine. The
chip contains a desiccated hydrogel with reagents needed for Plasmodium specific PCR. Chips can be stored at
room temperature and used on demand by rehydrating the gel with unprocessed blood, avoiding the need for
sample preparation. These chips were run on a custom-built instrument containing a Peltier element for thermal
cycling and a laser/camera setup for amplicon detection.
Results: This diagnostic was capable of detecting all Plasmodium species with a limit of detection for Plasmodium
falciparum of 2 parasites/μL of blood. This exceeds the sensitivity of microscopy, the current standard for diagnosis
in the field, by ten to fifty-fold. In a blind panel of 188 patient samples from a hyper-endemic region of malaria
transmission in Uganda, the diagnostic had high sensitivity (97.4%) and specificity (93.8%) versus conventional
real-time PCR. The test also distinguished the two most prevalent malaria species in mixed infections, P. falciparum
and Plasmodium vivax. A second blind panel of 38 patient samples was tested on a streamlined instrument with
LED-based excitation, achieving a sensitivity of 96.7% and a specificity of 100%.
Conclusions: These results describe the development of a lab-on-chip PCR diagnostic from initial concept to
ready-for-manufacture design. This platform will be useful in front-line malaria diagnosis, elimination programmes,
and clinical trials. Furthermore, test chips can be adapted to detect other pathogens for a differential diagnosis in
the field. The flexibility, reliability, and robustness of this technology hold much promise for its use as a novel
molecular diagnostic platform in developing countries.Background
Malaria is a blood-borne parasitic disease causing over
660,000 deaths each year, primarily in young children
from sub-Saharan Africa [1]. In the past decade, malaria
control efforts have focused on scale-up interventions
including use of insecticide treated bed nets, indoor re-
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unless otherwise stated.based combination therapy to reduce morbidity and
mortality. Still, in countries bearing the largest malaria
burden, access to quality diagnostics is limited [2,3]. Mi-
croscopy, if available, is the gold standard for malaria
diagnosis but in health centres with limited resources,
malaria is diagnosed presumptively in patients with fever
[4]. These practices lead to overtreatment and misdiag-
nosis of potentially fatal bacterial infections and are be-
coming less feasible in the face of emerging drug
resistance and costly new therapies [2,5,6]. As such, new
diagnostic practices are urgently needed. Furthermore,
as malaria control efforts intensify and countries progresstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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role in surveillance to identify sporadic outbreaks and
asymptomatic reservoirs of infection [7]. Immunochroma-
tographic rapid diagnostic tests (RDTs) provide an import-
ant alternative to microscopy at the point-of-care, but are
not without significant limitations, including decreased
sensitivity at lower levels of parasitaemia, inhibition at
high levels of parasitaemia (prozone effect), inability to
quantitate or distinguish malaria species in mixed infec-
tions, and failure to detect parasites with mutations in the
genes encoding certain target antigens [4,8,9]. While
strides have been made in improving RDT performance
[10], nucleic acid based diagnostics, including PCR and
isothermal amplification, provide superior sensitivity and
specificity [11]. However, the need for pre-analytic pro-
cessing, cold storage, and expensive equipment has
precluded the use of nucleic acid diagnostics in the field.
Lab-on-chip platforms have shown promise in overcom-
ing these barriers by adapting common laboratory tests to
a self-contained, portable, micro-scale format targeted to
the point-of-care [12]. In this study, the development of a
plastic hydrogel chip and a portable real-time PCR ma-
chine for malaria diagnosis is described.
Methods
Patient samples and controls
Archived, frozen samples from malaria patients with a
positive diagnosis by PCR were acquired from the
Provincial Laboratory for Public Health (ProvLab) in
Edmonton, Alberta. The blind panel run on the Gelcycler
was generated from samples collected in 2011–2012 in
Uganda from consenting pregnant women participat-
ing in a study to genotype parasite resistance [13] (dur-
ing antenatal care, at delivery and those with fever
attending outpatient clinics). Blood (4 mL) was sampled
by venipuncture, stored in EDTA vacutainers, and trans-
ferred to the Uganda Virus Research Institute for storage
at −20°C. Thick smears were stained by Giemsa and
malaria parasites counted against 200 leukocytes and
expressed as number of parasites per μL of blood assum-
ing a standard leukocyte count of 8,000/μL of blood. A
smear was considered negative after examining a mini-
mum of 100 high power fields with no parasites seen.
Microscopy was performed by a laboratory technician at
one of two health facilities in Mukono district. Coded
samples were aliquoted and shipped frozen for testing in
Alberta. Ethical approval was granted by the review boards
at the Uganda Virus Research Institute and Uganda
National Council for Science and Technology (Reference
HS 747). Use of samples from ProvLab and the Ugandan
study was approved by the Health Research Ethics Board
at the University of Alberta.
The blind panel run on the Accutas comprised ran-
domly chosen EDTA samples as positive and negativefor malaria DNA that were submitted during the first
seven months of 2011 for routine malaria diagnosis at
the Department of Clinical Parasitology, Hospital for
Tropical Diseases [14].
A nested PCR reaction [15] to amplify malarial DNA
was performed on all these samples in addition to rou-
tine diagnosis by microscopy. All PCR positive samples
were further characterized against the WHO Inter-
national Standard for Plasmodium falciparum by a real-
time PCR reaction [16]. Once a definitive malaria
diagnosis had been made for each sample the remainder
were anonymized and stored as surplus to diagnostic re-
quirements for use in ethically approved research pro-
jects. The panel consisted of positive samples infected
with the following species: P. falciparum (n = 25), Plas-
modium vivax (n = 2), Plasmodium ovale (n = 2), and
Plasmodium malariae (n = 1). Parasitemia ranged from
<5 to >1,000 parasites/μL blood. The panel also included
eight negative samples.
Plasmodium knowlesi purified genomic DNA (Malaria
Research and Reference Reagent Resource Center (MR4),
Manassas, VA) was diluted to 2 ng/mL in non-infected
blood to serve as a reference for this species. The negative
control used in this study was a hemoglobin tri-level con-
trol, level 2 (Stanbio, Boerne, TX) diluted 1:10 in water.
The positive control had the same composition as the
negative, with the addition of a consensus PCR product to
a final concentration of 105 copies/μL for hydrogel wax
chips and 102 copies/μL for hydrogel plastic chips.Parasite culture
Plasmodium falciparum parasites were grown in human
erythrocytes at 3-5% haematocrit as described [17]. Ring
stage parasites were enriched by sorbitol lysis [18],
counted, and diluted in whole blood. The diluted para-
sites were frozen until use.Reagents
The hydrogel mastermix contains reagents described
previously for direct amplification of DNA targets from
blood [19] and reagents for forming a polyacrylamide
gel. This mastermix was prepared with 1X Klentaq
Buffer (containing 3.5 mM Mg2+; DNA Polymerase
Technology, St. Louis, Mo), 40X SYBR Green I (Life
Technologies, Grand Island, NY), 1X PCR Enhancer
Cocktail (PEC-1) (DNA Polymerase Technology), 200
nM forward and reverse primers, 200 μM dNTPs, 0.03%
BSA, 4% acrylamide (Sigma St. Louis, Mo), 0.4% bis-
acrylamide aqueous solution (BioRad, Hercules, CA),
0.06% azobis (Wako, Richmond, VA), and 0.1% TEMED
(Sigma). For a 100 μL mastermix volume, 3 μL of Omni
KlenTaq enzyme was added (DNA Polymerase Technol-
ogy). Both consensus PCR primers [15,20], and species-
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gene of Plasmodium.
Hydrogel wax chips
A prototype consisting of a wax cassette in a 23.5 ×
32 mm aluminum pan was created wherein the hydrogel
is polymerized and desiccated on a coverslip above a
wax-bound “trench”. A polydimethylsiloxane (PDMS)
stamp was used to imprint 4 trenches in the wax. Three
coverslips (20 mm × 5 mm) were placed equally spaced
on top of the wax, perpendicular to the trenches, creat-
ing 12 covered slots for hydrogels. Coverslips were
sealed onto the wax by briefly heating the surface of the
coverslip between each trench with a soldering iron,
allowing the wax underneath to melt slightly. A 13 μL
aliquot of mastermix was added to each slot, creating a
“gel strip”. The gel strip was photopolymerized at room
temperature under UV light (367 nm) for 30 minutes.
Polymerized gels were desiccated under vacuum (23
inHg) for 1 hour at room temperature and used within
seven days. Chips were stored in dark conditions to pre-
vent photo-bleaching of SYBR green dye. Coverslips
were treated with 3-(trimethoxysilyl)propyl methacrylate
to promote adherence to the gel strip as described [23].
On desiccation, the gel shrinks away from the trench
and stays attached to the coverslip, creating a channel
underneath the strip where the sample can diffuse in.
Whole blood was diluted 1:10 with water, then 8.5 μL of
this sample mixture was applied underneath the cover-
slip/gel-strip. After the addition of samples and controls,
the wax cassette was incubated for 10 minutes at room
temperature then placed directly on the Peltier element
within the Gelcycler for thermocycling.
Hydrogel plastic chips
Plastic chips were manufactured by miniFAB (Scoresby,
Australia) by injection molding of cyclic olefin polymer
(COP1420R) into top (27 × 27 mm) and bottom pieces
(27 × 42 mm). To form the hydrogels, a 15 μL aliquot of
mastermix was first added to the wells in the top piece.
Next, the top piece was placed in a customized UV
illumination chamber and flooded with nitrogen for
2 minutes. The gel was photopolymerized at room
temperature under UV light (405 nm) for 30 minutes.
The chamber was flooded with nitrogen a second time
for 2 minutes, halfway into the UV treatment. This sus-
tained nitrogen overlay was needed to prevent oxygen
from inhibiting gel polymerization. The polymerized gels
were desiccated under vacuum (23 inHg) at least
20 hours at room temperature. To complete the process
of making a chip, a 10 μL aliquot of wax was added to
each reservoir in the bottom piece, and the top and bot-
tom pieces were fitted together. Wax in the bottom res-
ervoir melts during thermocycling to cover the gel andsample ports, preventing evaporation and further cross-
contamination that may occur at high denaturation tem-
peratures. A two-sided tape adhesive on the bottom
piece seals the chip upon assembly and prevents cross-
contamination between gel chambers. The assembled
plastic chips were used within 24 hours of preparation,
or vacuum-sealed in plastic, stored at room temperature
(22°C) in the dark, and tested within one month. With
this design, sample added via the sample port in the top
piece enters the lower reservoir and rehydrates the gel
in the well. However, to ensure efficient loading of the
sample in the validation experiments presented here,
8.5 μL of whole blood diluted 1:10 in water was added
directly to the gel in the well before assembly of the
chip. Samples were incubated prior to thermocycling as
described above. As opposed to the wax chips, which sit
freely on the Gelcycler Peltier element, the plastic chips
were secured onto the Peltier with a gantry to ensure
evenly distributed thermal transfer.
Instrumentation: Gelcycler and Accutas
The Gelcycler features a Peltier element for sample heat-
ing, components for stringent thermal regulation, a laser
and CCD camera for capturing fluorescence [24]. Con-
sensus PCR reactions for the hydrogel wax chip were
performed with a 10 minute initial denaturation step at
94°C, followed by 40 cycles of 94°C for 20 seconds, 58°C
for 30 seconds, 72°C for 30 seconds, and a 2 minute final
extension of 72°C. Reaction conditions for the hydrogel
plastic chips were the same as above, except the consen-
sus PCR annealing temperature was 60°C, and the
species-specific annealing temperature was 64°C. MCA
from 70-90°C was performed immediately after PCR.
Fluorescent images were obtained and analysed as de-
scribed [24] to generate real-time PCR and MCA curves
using in-house software that requires manual analysis. A
five-parameter sigmoid curve-fitting method using the
first derivative was created to calculate cycle threshold
(Ct) values. Samples were considered positive if they had
a Ct value of less than 40 and the expected MCA peak
profile. Conventional real-time PCR confirmation was
performed on panel samples as described in Taylor et al.
[19]. The Accutas system refines the Gelcycler and
brings many improvements. The modular design incor-
porates Design for Manufacturing principles to enable
low cost, high volume manufacturing of the system. The
Accutas system includes an LED light source rather than
a laser-based system, allowing lower power and safer op-
eration. The temperature-controlled environment allows
the Accutas to be run in a wider window of tempera-
tures. The temperature control of the Accutas was opti-
mized and is easily adaptable to new designs. The new
aluminum framed enclosure is more rugged for trans-
port in the field. The PC control software was rewritten
A B C
Figure 1 A prototype hydrogel wax chip and manufactured plastic chip for malaria diagnosis. (A) Core concept for hydrogel PCR. A single
hydrogel strip (yellow) is desiccated and adheres to one surface of the chip creating a channel underneath for sample delivery. Blood flows
through the channel by capillary force and is absorbed by the gel. (B) A wax chip with trenches overlaid with hydrogel bound to a glass coverslip.
Blood is manually loaded into the channel below each hydrogel strip. (C) A plastic chip composed of top and bottom pieces of molded plastic. The
gel is housed within a well in the top piece. In the current study, blood was added directly to the hydrogel in the open chip, and the two pieces of


































































Figure 2 Malaria detection on hydrogel wax chips. (A) The ‘Gelcycler’, a custom-built, miniaturized real-time PCR instrument. (B) Raw SYBR
green fluorescence images from positive and negative control wells in the wax chip. (C) Real-time PCR amplification curves and (D) melt curve
analysis of the negative (gray) and positive (red) controls in (B). (E, F) Plasmodium DNA detected from clinical samples and a spiked P. knowlesi
sample using PCR with conserved primers. Positive samples exhibit an amplification curve (E) and melt curve (F) at the appropriate melting
temperature for each species.
Taylor et al. Malaria Journal 2014, 13:179 Page 4 of 10
http://www.malariajournal.com/content/13/1/179
Taylor et al. Malaria Journal 2014, 13:179 Page 5 of 10
http://www.malariajournal.com/content/13/1/179as well to provide an easier, step-by-step user interface
with automated reporting at the end of each experiment.
Statistics
Analyses were performed using SAS/STAT 9.1. Confi-
dence intervals (95%) were calculated using the Wilson
score interval method.
Results
Test performance in prototype hydrogel chips
In previous studies “hydrogel” PCR technology was de-
veloped to package PCR reagents in a format that can be
stored and is easy to use [23]. This included the creation
of a customized field-ready real-time PCR machine, the
‘Gelcycler’. In a separate study, a conventional PCR
method for detecting malaria directly from blood sam-
ples, without the need for prior DNA purification, was
developed [19]. The goal was to translate this research
into a disposable lab-on-chip diagnostic that would find
practical application in field settings. The initial phase of
this work focused on creating a prototype chip to which
multiple blood samples could be applied and tested.
These prototype chips were created in the lab entirely
from readily available materials. Aluminum cosmetic
pans served as the base of the chip; these were filled
with molten wax and four separate troughs were created
using a stamp [24] (Figure 1A and 1B). Once the stampFigure 3 Diagnosis in hydrogel plastic chips. (A, B) On-chip detection o
sample with the consensus PCR primers. (C, D) Limit of detection analysis
in culture.was removed, glass coverslips cut to the appropriate size
were laid over the troughs in the hardened wax, generat-
ing discrete channels to contain the hydrogels. The
hydrogel mastermix including all of the reagents neces-
sary for real-time PCR from blood was added to each
channel underneath the coverslip. The mastermix was
polymerized and desiccated, yielding 12 self-contained
hydrogel units intended for 12 blood samples to be
tested in the PCR reaction [24,25]. During desiccation,
the hydrogel shrinks away from the wax trough but stays
attached to the coverslip, creating a route for sample de-
livery via the channel underneath each gel (Figure 1A).
Addition of blood to the chip rehydrates the gel within
minutes and the blood is retained within the gel unit.
During PCR, the wax melts and surrounds the hydrogels
attached to the coverslip. The hydrogels remain attached
in their original positions during PCR, and no cross-
contamination was observed with this chip configuration.
Prototype chips were run on the Gelcycler which per-
forms real-time PCR followed by melt curve analysis
(MCA) to confirm the specificity of the PCR product
(Figure 2A). In this reaction, consensus primers target a
region of the 18S rRNA gene from Plasmodium [19] and
amplified DNA is detected by SYBR green chemistry
(Figure 2B). Real-time PCR (Figure 2C) and MCA curves
(Figure 2D) using positive and negative controls demon-
strated high reproducibility. Using clinical samples fromf parasite DNA directly from clinical samples and a spiked P. knowlesi
with dilutions of ring-synchronized P. falciparum parasites grown
Figure 4 PCR sensitivity is maintained after storage. (A, B) Serial dilutions of P. falciparum cultures run on chips that were loaded with hydrogel
reagents, desiccated and stored for 4 months at 37°C.
Table 1 Demographic and clinical characteristics of
patients included in the blind panel from Uganda (n = 188)
Median age [range] 20 years [14 – 42]
Presentation
Asymptomatic (n [%]) 72 [38.3]
Clinical malaria (n [%]) 116 [61.7]
Pregnancy status
In antenatal care (n [%]) 184 [97.9]
At delivery (n [%]) 4 [2.1]
Median parasitemia [range] 440 parasites/μL [1 – 94800]
Taylor et al. Malaria Journal 2014, 13:179 Page 6 of 10
http://www.malariajournal.com/content/13/1/179patients with imported malaria in Canada, the consensus
reaction successfully amplified five species of Plasmo-
dium directly from blood (Figures 2E and 2F). The limit
of detection for P. falciparum was 2 parasites/μL, mea-
sured in serial dilutions of cultured parasites in whole
blood (Additional file 1).
Manufactured plastic chips for hydrogel PCR
In the next phase of chip development, an enclosed plas-
tic chip was designed that retained the key features of
the prototype wax chip and could be manufactured on a
large scale for use in the field (Figure 1C). The thermal
properties and auto-fluorescence of several types of plas-
tics were assessed and cyclic olefin polymer (COP1420R)
proved most compatible with real-time PCR. The top
piece of the chip was molded with 10 individual wells:
eight test wells and two controls. Two ports for sample
delivery are present on either side of each well. The
hydrogel mixture was added to each well, polymerized
and desiccated. A bottom piece of plastic was created
with reservoirs that align with the sample ports and
wells of the top piece. When the two pieces are adhered,
they form an enclosed chip with channels for sample de-
livery, similar in concept to the hydrogel wax chip. The
assembled plastic chips are easily packaged and stored.
Blood samples were simply diluted in water for lysis
(2 μL of blood added to 18 μL of water) and 8.5 μL was
added to the hydrogel on the chip. This corresponds to
approximately 0.85 μL of the original blood sample. To
ensure accuracy in the current study, samples were
added to each hydrogel prior to chip assembly. Positive
and negative controls were included in each chip to en-
sure on-board quality control for the reagents and amp-
lification reactions (Additional file 2).
Test performance in plastic chips
Compared with our prototype wax chip, the hydrogel
plastic chip showed similar, if not superior performance
of species coverage (Figure 3A and 3B) and limit of de-
tection (2 parasites/μL; Figure 3C and 3D). This sensitiv-
ity corresponds to 1.7 parasites per 0.85 μL of bloodsampled in each well. With approximately seven copies
of the target gene per parasite genome [26], this equates
to 12 gene copies detected. The plastic chip demon-
strated excellent performance within a range of 2 × 105
to 0.2 parasites/μL, consistent with parasite levels ob-
served in the field.
To assess the stability of the reagents at high tempera-
tures, chips were loaded with hydrogel reagents, desiccated,
sealed, and stored for 4 months at 37°C (Figure 4A and
4B). The sensitivity of the PCR was maintained after stor-
age with detection at concentrations of 0.5 parasites/μL.
Validation of plastic chips
The plastic chips were further validated using a blind
panel of 188 samples from pregnant women residing in
a hyper-endemic region in Uganda. Women were either
attending antenatal clinics (98%) or in delivery (2%) at
the time of blood collection and most presented with
fever (Table 1). Based on microscopy performed at the
local hospital in Uganda, 142 samples were positive with
a median parasitaemia of 440 parasites/μL. The chip had
very high sensitivity compared with microscopy (96.5%;
Table 2). Specificity was low (63.0%), which was ex-
pected given that the analytical sensitivity of the chip is
at least one order of magnitude greater than microscopy.
Importantly, the chip detected 17 positive samples that
were negative by microscopy; 13 were from asymptomatic
patients and four with acute malaria. For comparison, and
Table 2 Performance characteristics of the hydrogel plastic chip compared with microscopy and conventional real-time PCR
Chip PCR
Pos (n) Neg (n) Sensitivity* (95% CI) Specificity* (95% CI) Kappa (95% CI)
Microscopy Pos (n) 137 5 96.5% (92.0 – 98.5) 63.0% (48.6 – 75.5) 0.653 (0.521 – 0.785)
Neg (n) 17 29
Conventional real-time PCR Pos (n) 152 4 97.4% (93.5 – 99.0) 93.8% (79.9 – 98.3) 0.890 (0.803 – 0.976)
Neg (n) 2 30
*Determined using microscopy or conventional real-time PCR as the comparator.
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a conventional real-time PCR platform using the direct
from blood assay [19]. The chip had a sensitivity of 97.4%
and specificity of 93.8% compared with conventional real-
time PCR. The four samples that were positive by conven-
tional real-time PCR but negative on the chip had cycle
threshold (Ct) values >38, suggesting they were very low
level infections and perhaps undetected due to sampling
error. Overall concordance between the two PCR methods
was 96.8% with a kappa statistic of 0.890.Malaria speciation on plastic chips
In many malaria-endemic regions, multiple species of
Plasmodium co-exist which require specific treatment
regimens and targeted control measures. The consensus
PCR is unable to discriminate between species based on0
15000
30000





































Figure 5 On-chip detection of P. falciparum and P. vivax. Clinical samp
a 1:1 mixture of each species (red) or uninfected (gray), were tested on hydro
P. vivax (C, D). Amplification (left panels) for each species was confirmed by mmelt curve analysis (Figure 3B) and primer competition
would prevent detection of mixed infections. Species-
specific primers were designed that amplify the two major
species of Plasmodium, P. falciparum and P. vivax, from
the same sample but in separate wells on the chip. Follow-
ing testing for cross-reactivity, one primer set for each
species was identified that specifically amplifies P. falcip-
arum (Figure 5A and 5B) and P. vivax (Figure 5C and 5D)
from single infections and a 1:1 mixture of both species.
Addition of these reactions to the chip expands its func-
tionality from genus to species-level diagnosis.Development and validation of a field-ready device
Once proof-of-concept was demonstrated on the Gelcy-
cler prototype, a new instrument that streamlines manu-
facturing and usability in the field, called the ‘Accutas’,0
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les from patients infected with P. falciparum (blue) and P. vivax (green),
gel plastic chips with PCR primers specific for P. falciparum (A, B) and
elt curve analysis (right panels).
A B
Figure 6 The ‘Accutas’ system. Shown with a laptop in (A) and with the top open (B), this smaller, rugged design features an LED light source,
operability within a wider ambient temperature range, and automated data reporting.
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provements over the Gelcycler: an LED light source in-
stead of a laser for fluorescence detection, temperature-
controlled environment, framed enclosure, and software
with a simple user interface. To assess the performance
of the Accutas, a third-party evaluation with a blind
panel of 38 samples from the Hospital for Tropical Dis-
eases in London was conducted. Samples were collected
from patients with imported malaria, including four spe-
cies of Plasmodium, and negatives (Table 3). Of 30 posi-
tive samples, 29 were detected on the Accutas, yielding a
sensitivity of 96.7%. The specificity was 100%. This third
party evaluation was completed before the speciation re-
action had been validated on the Gelcycler.
Discussion
Accessible, quality diagnostics with low infrastructure
requirements are expected to profoundly impact public
health and child mortality from malaria [3]. They also
support new ‘test-before-treat’ policies to curb the emer-
gence of drug-resistant parasites and discourage presump-
tive diagnosis based on fever [27,28]. Highly sensitive
molecular technologies exist with the potential to meet
this critical need [8,11], yet few have overcome the bar-
riers of sample preparation, cold storage, cost, complexity
and infrastructure requirements for use in low-resource
settings [29]. The recent clinical evaluation of a commer-
cial loop-mediated isothermal amplification (LAMP) kitTable 3 Third party assessment of the Accutas (n = 38)
Chip PCR
Pos (n) Neg (n) Sensit
Microscopy Pos (n) 29 1 96.7%
Neg (n) 0 8that amplifies parasite DNA with minimal extraction steps
addresses many of these issues and demonstrates that mo-
lecular testing in the field is feasible [14,30,31]. However,
while the innovations present in field-ready LAMP kits
are commendable, a separate sample preparation process
is still a necessary part of the procedure. This step, even in
streamlined self-contained form provided by commercial
kits, can be a significant barrier to implementation of a
diagnostic test in resource-limited areas.
In this work a PCR-based diagnostic for malaria
intended for use at or near the point-of-care is pre-
sented. The platform consists of hydrogel chips run on a
customized portable real-time PCR machine. The hydro-
gel chips are disposable, do not require a cold-chain,
and can be stored and used on demand for a result in
less than two hours. PCR performed directly with unpro-
cessed blood eliminates a major obstacle to adopting this
technology outside of reference or research labs, and
simplifies the testing for unskilled users. The entire sys-
tem was designed to be low-cost for use in developing
countries. The chips use small volumes of master mix
(15 μL per test), and the material cost for the chips will
be further reduced to under $1 USD per test with scaled
production. Through innovative engineering and with
mass production, the real-time PCR instrument can be
manufactured for less than $2,000 USD. Quality optics
constitutes the major share of component costs, but is
essential to maintain sensitive fluorescence detection.ivity (95% CI) Specificity (95% CI) Kappa (95% CI)
(83.3 – 99.4) 100% (67.6 – 100.0) 0.924 (0.778 – 1.000)
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can be supplied by a variety of power sources include
the grid, dry cells, generators or photovoltaic systems.
The amount of power required to run the device is
equivalent to a car battery, which can be used to power
the device in field settings where the supply of electricity
is unstable. In the next generation of the platform, direct
loading of the chip and a battery-operated instrument
that provides a result within an hour will fully adapt the
technology to the constraints of the field.Conclusions
The technology described in this study has the potential
to make major inroads by supporting key areas of mal-
aria control: as a diagnostic for acute malaria, for sur-
veillance in elimination settings, and as a tool in clinical
evaluations of new drugs and vaccines. Importantly,
there are numerous applications of this technology be-
yond malaria. The platform has the inherent flexibility
to detect any molecular target simply by using different
PCR primers in the hydrogel mix. This marks an import-
ant advantage over other approaches, such as LAMP,
that require extensive primer validation. Tests for other
disease targets in different specimen types are readily
adapted to our platform, for example, sexually transmit-
ted infections (STI) detected from urine and genital
swabs [24]. Furthermore, as shown here with malaria
species, and separately for STI targets [24], a single pa-
tient sample could be tested for multiple targets simul-
taneously, providing a rapid differential diagnosis. Chips
can be tailored to test for different pathogens, species,
or genetic markers (including drug resistance markers),
depending on the clinical or public health need. In sum-
mary, this work showcases a novel molecular technology
that can make an important contribution to the diagnosis
and surveillance of infectious diseases in low-resource
settings.Additional files
Additional file 1: Limit of detection analysis on hydrogel wax chips.
(A) PCR and (B) MCA performed using dilutions of ring-synchronized
P. falciparum parasites grown in culture and serially diluted in whole blood.
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